Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. [electronic resource]
Producer: 20120214Description: 6368-79 p. digitalISSN:- 1528-0020
- Adult
- Animals
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- BRCA1 Protein -- genetics
- Boronic Acids -- administration & dosage
- Bortezomib
- Cell Line, Tumor
- Cells, Cultured
- DNA Repair -- drug effects
- Enzyme Inhibitors -- administration & dosage
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- Mice
- Mice, SCID
- Multiple Myeloma -- drug therapy
- Poly(ADP-ribose) Polymerase Inhibitors
- Proteasome Endopeptidase Complex
- Proteasome Inhibitors
- Pyrazines -- administration & dosage
- RNA, Messenger -- metabolism
- Rad51 Recombinase -- genetics
- Survival Analysis
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.